

## Special Issue

# Gut Microbiota and Metabolites: Novel Strategies for Intestinal Inflammation Therapy

### Message from the Guest Editor

Inflammatory bowel disease (IBD) is a family of conditions characterized by chronic, relapsing inflammation of the gastrointestinal tract. IBD, which can be roughly sub-divided into ulcerative colitis (UC) and Crohn's disease (CD), is estimated to affect as many as 5 million people worldwide. Although various treatment regimens have been developed in preceding decades to control IBD symptoms, there is no cure for IBD. Thus, the development of improved IBD therapeutics is a research field of particular importance to patient well-being. Modern IBD treatment guidelines focus on the induction and maintenance of clinical and endoscopic remission, often using a combination of immunosuppressant antibodies ("biologics") and older, well-established small molecules such as methotrexate and thiopurines. Other alternative therapies such as fecal microbiota transplant (FMT) have also been investigated as a means of achieving and maintaining remission. In this Special Issue of *Pharmaceuticals*, we explore various strategies for the treatment of IBD with a focus on recent discoveries and/or especially novel approaches.

---

### Guest Editor

Dr. Alexander S. Dowdell

1. Mucosal Inflammation Program and Division of Gastroenterology and Hepatology, Department of Medicine, University of Colorado, Aurora, CO, USA

2. Department of Medicine, Rocky Mountain Veterans Regional VA Medical Center, Aurora, CO, USA

---

### Deadline for manuscript submissions

25 June 2026



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/264812](https://mdpi.com/si/264812)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)